Thrive Partners VII Growth GP, LLC
Known title: 10% OwnerCIK: 0001877735
Thrive Partners VII Growth GP, LLC's purchase track record
How the stock did after each of Thrive Partners VII Growth GP, LLC's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 5 since August 20, 2021
Stock higher 6 months later
20%
3 months: 20%
Median 6-month return
-48.4%
3 months: -24.1%
Beat the S&P 500
20%
median -46.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/20/2024 | OSCR | $3.19M | -5.9% | -12.6% | -1.2% |
| 11/11/2024 | OSCR | $19.87M | +6.7% | +21.9% | -2.6% |
| 9/9/2021 | OSCR | $33.77M | -44.5% | -51.3% | -5.2% |
| 8/30/2021 | OSCR | $18.30M | -39.3% | -52.2% | -3.4% |
| 8/20/2021 | OSCR | $22.48M | -24.1% | -48.4% | -2.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| OSCR | ▲ Buy | Open Market | 100,000 | $1.7M | 11/21/2024 | View on chart |
| OSCR | ▲ Buy | Open Market | 88,395 | $1.5M | 11/20/2024 | View on chart |
| OSCR | ▲ Buy | Open Market | 158,732 | $2.5M | 11/14/2024 | View on chart |
| OSCR | ▲ Buy | Open Market | 185,790 | $3.0M | 11/14/2024 | View on chart |
| OSCR | ▲ Buy | Open Market | 358,619 | $4.9M | 11/13/2024 | View on chart |
| OSCR | ▲ Buy | Open Market | 420,819 | $5.8M | 11/12/2024 | View on chart |
| OSCR | ▲ Buy | Open Market | 276,040 | $3.7M | 11/11/2024 | View on chart |
| OSCR | ▲ Buy | Open Market | 323,725 | $5.8M | 9/15/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 515,344 | $9.3M | 9/14/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 156,324 | $2.6M | 9/13/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 221,228 | $3.9M | 9/13/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 250,000 | $4.4M | 9/10/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 180,891 | $3.1M | 9/9/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 263,821 | $4.7M | 9/9/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 157,135 | $2.9M | 9/3/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 167,966 | $2.9M | 9/2/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 160,385 | $2.9M | 9/2/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 93,836 | $1.4M | 8/31/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 211,703 | $3.3M | 8/31/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 274,697 | $4.0M | 8/30/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 55,188 | $843K | 8/30/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 217,590 | $3.1M | 8/27/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 204,811 | $2.8M | 8/26/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 31,794 | $419K | 8/25/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 1,074,342 | $13.6M | 8/24/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 125,900 | $1.6M | 8/23/2021 | View on chart |
| OSCR | ▲ Buy | Open Market | 68,042 | $913K | 8/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Oscar Health Analyst Target Rises to $34.19
Analysts raised the consensus price target for Oscar Health by 12.09% to $34.19. This adjustment follows recent updates to the company's earnings roadmap and new product initiatives. The stock is currently trading near the upper end of its 52-week range, reflecting renewed interest in its growth prospects.
Oscar Health Analyst Target Rises to $34.19. Analysts raised the consensus price target for Oscar Health by 12.09% to $34.19. This adjustment follows recent updates to the company's earnings roadmap and new product initiatives. The stock is currently trading near the upper end of its 52-week range, reflecting renewed interest in its growth prospects.